Get the Stockscreener App
3.92
1.82%
0.07
After Hours:
3.92
Ironwood Pharmaceuticals Inc stock is traded at $3.92, with a volume of 1.93M.
It is up +1.82% in the last 24 hours and down -6.22% over the past month.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
See More
Previous Close:
$3.85
Open:
$3.86
24h Volume:
1.93M
Relative Volume:
0.68
Market Cap:
$645.28M
Revenue:
$296.15M
Net Income/Loss:
$24.02M
P/E Ratio:
32.50
EPS:
0.1206
Net Cash Flow:
$127.01M
1W Performance:
+9.50%
1M Performance:
-6.22%
6M Performance:
+24.05%
1Y Performance:
+532.16%
1-Day Range:
$3.80
$3.93
1-Week Range:
$3.42
$3.94
52-Week Range:
$0.55
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.92 | 633.76M | 296.15M | 24.02M | 127.01M | 0.1206 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant - Stock Titan
Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant - Stock Titan
Kyverna Therapeutics appoints Greg Martini as CFO - MSN
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement? - Insider Monkey
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 - MSN
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears - MSN
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch - citybiz
Top Small-Cap Stocks to Watch: Ironwood Pharmaceuticals (IRWD) L - GuruFocus
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood Pharma drops after CFO transition - MSN
Ironwood Pharmaceuticals: Still A Profitable Opportunity (NASDAQ:IRWD) - Seeking Alpha
Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A - Stock Titan
Ironwood Pharmaceuticals, Inc.Class A Common Stock (NQ: IRWD - FinancialContent
Renaissance reports 4.90% stake in Ironwood (IRWD) - Stock Titan
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating - Moomoo
Ironwood Pharma Announces CFO Resignation and Interim Successor - The Globe and Mail
Ironwood stock down despite Q1 earnings and revenue beat - MSN
Earnings call transcript: Ironwood’s Q1 2026 earnings beat forecasts, stock dips - Investing.com
Ironwood Pharmaceuticals: CFO Resignation Knocks SharesA Downgrade Is Due (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) Shares Drop 12% After CFO Resignation Announcement - GuruFocus
Ironwood Pharma stock drops after CFO exit (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details and Regulatory Disclosures - Minichart
Ironwood Pharmaceuticals IncGregory Martini resigns as CFO effective May 15, 2026SEC filing - marketscreener.com
[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event - Stock Titan
TradingKey - TradingKey
Ironwood Pharmaceuticals stock (US46333X1081): Revenue surge and earnings beat signal turnaround - AD HOC NEWS
Ironwood Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-05-11 - Seeking Alpha
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: Ironwood Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - 富途牛牛
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat - sharewise.com
Ironwood Pharmaceuticals Q1 Earnings Call Highlights - sharewise.com
Q1 2026 Ironwood Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ironwood: Q1 Earnings Snapshot - theheraldreview.com
Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge - Stock Titan
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):